Radspherin Drug Asset Due Diligence Report 2026

This Radspherin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Radspherin can convert its Small molecule drug, Therapeutic radiopharmaceuticals profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Radspherin (query alias: Radspherin)
Modality / target	Small molecule drug, Therapeutic radiopharmaceuticals; Not disclosed; Ionising radiation emitters
Highest global status	Phase 2
Originator	Oncoinvent ASA (Old)
Active developers	Oncoinvent ASA (Old)

The MCP disease footprint includes Ovarian Cancer, Colorectal Cancer, Peritoneal Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06504147	Phase 2	Recruiting	114	Primary endpoint not disclosed in English source
NCT03732768	Phase 1	Completed	21	Primary endpoint not disclosed in English source
NCT03732781	Phase 1/2	Completed	47	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Phase 1; n=10; evaluation: Positive. Reported fields: Recurrence rate = 10 % ; Recurrence rate = - 40 %

15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.

Phase 1/2; n=23; evaluation: Positive. Reported fields: mPFS = NR

Oncoinvent updates: Phase I dose escalation completed successfully in two indications Phase 2 A inclusion has started

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: clincal endpoint = Radspherin® has demonstrated attractive biodistribution, favorable tolerability and potential signals of efficacy.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Radspherin addresses Ovarian Cancer, Colorectal Cancer, Peritoneal Neoplasms. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug, Therapeutic radiopharmaceuticals—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-06-30	BerGenBio and Oncoinvent announce that they have entered into a merger agreement to combine the two companies through a statutory merger, where BerGenBio will be the acquiring entity.	Phase 2	US$16.2M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO